Impact of Plasma Indoxyl Sulfate on One-year Adverse Events in Chronic Kidney Disease Patients with Heart Failure: a Prospective, Multicenter Cohort Study

Impact of Plasma Indoxyl Sulfate on One-year Adverse Events in Chronic Kidney Disease Patients with Heart Failure: a Prospective, Multicenter Cohort Study - IDSTOP-HF study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035850

Enrollment

312

Registered

2019-03-01

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure Chronic kidney disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)history of hospitalization for heart failure 2)CKD stage 3B, 4, and 5 3)age >=20 and <85 4)patient who gave a written informed consent after sufficient explanation

Exclusion criteria

Exclusion criteria: 1)history of hospitalization within 30 days 2)patient taking spherical carbonaceous adsorbent 3)patient on hemodialysis 4)patient with Nephrotic Syndrome 5)patient wiht polysistic kidney 6)patient who took any unaprooved medicine wihtin 180 days 7)patient wiht prognosis less than 12 months 8)woman who is pregnant 9)patient who is unsuitable for this study by the investigator

Design outcomes

Primary

Measure	Time frame
Incidence of all cause death, non fatal myocardial infarction, non fatal stroke, and hospitalization for heart failure during one-year follow up after acquisition of indoxyl sulfate concentration.	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Cardiovascular Medcine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results